METHOD FOR CONSTRUCTING AND MODIFYING LARGE DNA MOLECULES

This invention provides a method for combining overlapping DNA molecules comprising: (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) tagging the first DNA fragment with a selectable marker; (c) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (d) linearizing the DNA-vector complex; and (e) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule; and (f) removing the selectable marker, thereby generating a combined DNA molecule. The invention further provides a vector for retrieving and inserting a selected DNA molecule into a target DNA molecule.
METHOD FOR CONSTRUCTING AND MODIFYING LARGE DNA MOLECULES

This application claims priority of provisional application U.S. Serial No. 60/490,025, filed July 24, 2003, the contents of which are incorporated herein by reference.

Throughout this application, various publications are referenced. Full citations for these publications may be found listed at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as of the date of the invention described and claimed herein.

BACKGROUND OF THE INVENTION

The ability to manipulate large DNA fragments is very important to contemporary biology. Although recombinant techniques were developed more than 25 years ago, improved methodologies remain highly prized, especially to aid functional genomic studies (1, 2). Conventional approaches for the manipulation of DNA are multi-step and time-consuming, involving the digestion of DNA by appropriate restriction enzymes followed by ligation into a suitable cloning vector. A critical factor in the success of traditional DNA manipulation is the length of the DNA to be engineered. Due to the demands of restriction specificity it is very difficult to manipulate DNA molecules of more than 20,000 base pairs using traditional restriction-ligation methods (3). This is of particular concern to bacterial artificial chromosome (BAC) engineering, where there is often a need to engineer DNA fragments large enough to contain the appropriate regulatory elements for a certain gene’s expression (4). BACs have become powerful tools in
functional genomic studies (1), so better methods for precisely manipulating BAC DNA are required.

Recently, scientists have developed a new method, known as recombineering, to manipulate large DNA fragment (5-10), and have overcome the difficulties in traditional BAC DNA engineering. These methods have been based either on the RecET proteins or the λ-recombination proteins. The RecET system is based on homologous recombination mediated by the RecE and RecT proteins. The Red system is based on homologous recombination mediated by three λ-recombination proteins, exo (α), bet (β) and gam (γ), collectively known as the Red proteins. The Red system is similar to the RecET system, but has been shown to be 50-100 times more efficient in Escherichia coli (6). A modified DH10B strain, called DY380, harboring a defective λ-prophage carrying the red genes under the tight control of the temperature sensitive λ-cI857 repressor has been created (10). Incubation of DY380 cells at 42°C results in the inactivation of the temperature-sensitive λ repressor, and hence the production of the exo (α), bet (β) and gam (γ) proteins, enabling recombination. In the present study, a two-step approach based on the Red-mediated recombination was developed. In the first step, retrieval, a large DNA fragment is retrieved from a BACs. In the second step, recombination, the large DNA fragment is inserted into a second BAC to form the unified BAC containing the entire desired sequence. This task would be extremely difficult by conventional means.
SUMMARY OF THE INVENTION

This invention provides a method for combining overlapping DNA molecules comprising the steps of (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (c) linearizing the DNA-vector complex; and (d) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule.

This invention further provides a method for combining overlapping DNA molecules comprising the steps of: (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) tagging the first DNA fragment with a selectable marker; (c) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (d) linearizing the DNA-vector complex; and (e) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule; and (f) removing the selectable marker, thereby generating a combined DNA molecule.

This invention also provides the above methods further comprising the step of inserting the combined DNA molecule into a third DNA fragment using homologous recombination.

Finally, the invention provides a vector for retrieving and inserting a selected DNA molecule into a target DNA molecule, comprising: (a) a first DNA fragment homologous with a first region of the selected DNA molecule; (b) a second DNA fragment homologous with a second region of the selected DNA molecule; and (c) a third DNA fragment containing a rare restriction site.
BRIEF DESCRIPTION OF THE FIGURES

FIGURE 1
General Experimental Strategy for BAC Engineering.

Hatched pattern represents the Sp6 fragment of BAC. Diamond pattern represents the T7 fragment of BAC. Vertically striped pattern represents Arm A, the breakpoint of Tyrp-1 gene of Tyrp-1 BAC1. Diagonally striped pattern represents Arm B at the end of Tyrp-1 gene of BAC1. Solid rectangles represent exons of Tyrp-1 gene. Double italic lines represent disproportional genomic DNA. Amp is Ampicillin resistance gene. Ori refers to origin of replication. Ts represents transcriptional site. represents PolyA site. represents 3,749-bp frt\textsuperscript{Kan}\textsuperscript{R}-frt cassette. represents frt site. represents 1,896-bp of loxP-\textsuperscript{Kan}\textsuperscript{R}-loxP cassette.

(A). Overall Aim of Experiment. Top left, Tyrp-1 BAC1 containing Tyrp-1 exons 1 to 8 and the 3' downstream region. Top right, Tyrp-1 BAC2 containing the Tyrp-1 5' region and exon 1 and 2. Bottom: the final extended unified Tyrp-1 BAC containing the Tyrp-1 5' region, all the exons, and a 16.5-kb 3' region. 31,160-bp is the distance between the 3' break point of Tyrp-1 BAC2 and the last base pair in the extended unified Tyrp-1 BAC.

(B). Step one: 1\textsuperscript{st} Round Retrieval (upper left)
A kanamycin gene is first inserted into Tyrp-1 BAC1. The Tyrp-1 genomic DNA tagged by the kanamycin gene is then cloned into the retrieval vector (pBRBAC-AB). The positions of the primers which were used to amplify two homology arms are indicated by F3 & R3 and F5 & R5. In the retrieval vector, the ampicillin gene and origin of replication site are indicated by open arrows, the location of primers used to amplify the pBRBAC-AB retrieve vector are shown as thick closed arrows (R3 and F5). Homologous recombination events
are denoted by crosses. NotI cleavage sites are also shown.

(C). Step two: 1st Round Recombination (upper right)
Linearized Tyrp-1 genomic fragment containing Tyrp-1 exon 1-8 and 4 kb 3' region was recombined with Tyrp-1 BAC2 through the homologous ArmA and Sp6 DNA regions. The resulting Tyrp-1 BAC3 and the unified Tyrp-1 BAC contained the 5' regulatory region, all the Tyrp-1 exons and a 4 kb 3' downstream region. The position and orientation of primers (F1, R1, F2, R2, F4, F5, Sp6 and R5) that were used to detect and sequence the BACs are shown.

(D). 2nd Round Recombination (lower)
A second round of retrieval-recombination was carried out with the unified Tyrp-1 BAC and a 19,891-bp fragment downstream of exon 8 to generate an extended unified Tyrp-1 BAC. Wave line pattern represents a long homologous arm at Tyrp-1 intron 7 upstream of the frt site in the unified Tyrp-1 BAC. The position and orientation of the primers (F6, F7, R6, and BAC-Sp6-R) that were used to detect the extended unified Tyrp-1 BAC are shown.

FIGURE 2
(A). Identification of clones containing the retrieved fragment (1st round).
The left panel shows the digestion pattern of the retrieved BAC fragment. M: λ/HindIII DNA, Different clones labeled 1 to 6 were digested by restriction enzymes labeled above. Clones 1 to 5 show the expected digestion pattern. The right panel shows a 25.4kb NotI-linearized pBRBAC-AB construct containing the 22.5kb retrieved fragment.

(B). Verification of Tyrp-1 BACs with PCR.
A PCR product of 3.3kb by primer pair (F2+R2) can only be generated after homologous recombination occurred between the retrieved DNA
...and Tyrp-1 BAC2 to generate Tyrp-1 BAC3 and Tyrp-1 BAC. The four figures show the PCR verification of the full length Tyrp-1 BAC3 and Tyrp-1 BAC with different primer pairs (F1+R1, F2+R2, F4+Sp6, and F5+R5). Each picture shows a band of expected size. M: 1kb plus Marker. Template DNAs used are indicated by numbers above each lane. (1) Tyrp-1 BAC3; (2) unified Tyrp-1 BAC; (3) Tyrp-1 BAC2; (4) PCR negative control (water); (5) Tyrp-1 BAC1.

(C). Characterization of Tyrp-1 BACs by DNA fingerprint

The figure shows the DNA fingerprint results. The digestion pattern of unified Tyrp-1 BAC (labeled as 3) is very similar to that of the Tyrp-1 BAC2 (labeled as 2), but it also contains fragments unique to Tyrp-1 BAC1 (labeled as 1). The white arrows indicate DNA fragments present in unified Tyrp-1 BAC as well as in either Tyrp-1 BAC2 or Tyrp-1 BAC1, but not both. M1: λ/HindIII DNA. M2: 1kb plus Marker. The restriction enzymes used are listed at the top of each panel.

(D). PCR verification of 2nd round recombination products

The two figures show the PCR verification of the second round recombination products. Two PCR products of 1.38kb (left panel) and 6.2 kb (right panel) by primer pair (F7+BAC-Sp6-R) and (F6+R6), respectively, can only be generated after the second round recombination has occurred between the 19,891-bp retrieved DNA and Tyrp-1 BAC, creating the extended unified Tyrp-1 BAC. Each figure shows bands of the expected size. M: 1kb plus Marker. Template DNAs used are indicated by numbers above each lane. Lane 1: Clone 1 of extended unified Tyrp-1 BAC; Lane 2: Clone 2 of extended unified Tyrp-1 BAC; Lane 3: unified Tyrp-1 BAC.

FIGURE 3
Three Rounds of Recombination
Linearized BAC1 is recombined with a DNA fragment through the
homologous ArmA and Sp6 DNA regions to form BAC2. A second round of recombination is carried out with BAC2 and a downstream DNA fragment to generate an extended unified BAC3. A third round of recombination is carried out with BAC3 and a downstream DNA fragment to generate BAC4.

FIGURE 4
Retrieval Vector
A, B and Sp6 fragments represent the homologous arms. Retrieval is achieved by the homologous ArmA and ArmB. Targeted recombination is performed through the homologous ArmA and Sp6 DNA regions.
DETAILED DESCRIPTION OF THE INVENTION

Definitions:

As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.

As used herein, homologous shall mean having the same nucleic acid sequence.

As used herein, a rare restriction site shall mean a nucleic acid sequence which occurs infrequently in the genome and is recognized by a restriction enzyme. Such rare restriction enzymes may be, but are not limited to, NotI, SmaI or SfiI.

Embodiments of the invention:

This invention provides a method for combining overlapping DNA molecules comprising the steps of (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (c) linearizing the DNA-vector complex; and (d) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule.

In one embodiment, the DNA fragments are genomic DNAs or cDNAs. In another embodiment, the DNA fragments comprise at least 20 kb. The DNA fragments may comprise bacterial artificial chromosomes (BACs), mouse artificial chromosomes (MACs) or human artificial chromosomes (HACs).

In a further embodiment, the retrieval vector comprises an Sp6 or
other fragments homologous to the target vectors. In another embodiment, the homologous recombination is Red-mediated homologous recombination.

The above method may further comprise the step of inserting the combined DNA molecule into a third DNA fragment using homologous recombination.

This invention further provides a method for combining overlapping DNA molecules comprising the steps of: (a) providing first and second DNA fragments, the first having a region homologous to a region in the second; (b) tagging the first DNA fragment with a selectable marker; (c) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex; (d) linearizing the DNA-vector complex; and (e) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule; and (f) removing the selectable marker, thereby generating a combined DNA molecule.

In one embodiment, the DNA fragments are genomic DNAs or cDNAs. In another embodiment, the DNA fragments comprise at least 20 kb. The DNA fragments may comprise bacterial artificial chromosomes (BACs), mouse artificial chromosomes (MACs) or human artificial chromosomes (HACs).

In a further embodiment, the retrieval vector comprises an Sp6 fragment. In another embodiment, the homologous recombination is Red-mediated homologous recombination.

The above method may further comprise the step of inserting the combined DNA molecule into a third DNA fragment using homologous recombination.

Finally, the invention provides a vector for retrieving and
inserting a selected DNA molecule into a target DNA molecule, comprising: (a) a first DNA fragment homologous with a first region of the selected DNA molecule; (b) a second DNA fragment homologous with a second region of the selected DNA molecule; and (c) a third DNA fragment containing a rare restriction site.

The following experimental details are intended to be exemplary of the practice of the present invention, and should not be construed to limit the scope of the invention in anyway.
EXPERIMENTAL DETAILS

Synopsis

Recombinogenic engineering or recombineering is a powerful new method to engineer DNA without the need for restriction enzymes or ligases. Described below is a general method of using recombineering to combine overlapping bacterial artificial chromosomes (BACs) to built larger, unified BACs. In order to test the feasibility of using recombineering to combine two large DNA fragments (>20 kb), a unified BAC was constructed containing the full-length Tyrosinase-related protein-1 gene (Tyrp-1) from two library derived BACs, one containing the 5' regulatory elements, and the other containing the 3' coding exons. This was achieved using a two-step homologous recombination method enabled by the bacteriophage lambda Red proteins. In the first step, retrieval, a large DNA fragment (~22kb) was retrieved from one of the original BACs. In the second step, recombination, the retrieved DNA fragment was inserted into the second original BAC to form the unified BAC containing all the desired Tyrp-1 sequence. To further demonstrate the general applicability of this approach, an additional DNA fragment (~20kb) was inserted into the unified BAC downstream of the coding region. This method should prove very useful for enabling BAC manipulation in a variety of scenarios.

Materials and Methods

Enzymes, Media and Bacterial strains
Restriction enzymes were purchased from New England Biolabs unless indicated otherwise. T4 DNA ligase was from Gibco. Chloramphenicol (Cm), Kanamycin (Kan) and Ampicillin (Amp) were from Sigma. E. coli transformants were selected on tryptone-yeast extract agar medium containing the appropriate antibiotic at 12.5, 15 and 50µg/ml,
respectively. Primers were from Gensetoligo (Singapore). Plasmids were purified using a Qia Prep mini-prep kit (QIAGEN). PCR products and restriction enzyme digest products were recovered with GeneElut™ Agarose spin columns (Sigma). The genotype of DY380 (a gift from D. Court) is DH10B [\lambda cl857 (cro-bioA) <> tet] that means it harbors a defective λ-prophage carrying the repressor genes, but tet replaces the segment between cro and bioA in DY380 strain. The genotype of 294-Flp was generated by integrating 705-Flp into the lacZ locus of E. coli strain, MM294 (12) (a gift from AF Stewart).

Construction of plasmids

Two adjacent DNA fragments (70bp and 500bp) from the 3’ portion of Tyrp-1 BAC1 were amplified by PCR and cloned into the SalI and SacI sites of the pIGCN21 plasmid containing a frt-Kan^R-frt cassette (10) to generate the pIGCN21-Typrp1 plasmid. The 70bp-and-500bp-flanked frt-Kan^R-frt cassette was then amplified from the pIGCN21-Tyrepl plasmid with PCR primers (5’-TTTGTGACCGCTGTTCAGCCTTCAACAACC-3’ and 5’-TTTGAAGCTCCATGTGTGGCAAGGACTGTGAC-3’) and used to tag the Tyrp-1 BAC1.

The pBRBAC was constructed by subcloning a 870-bp EcoR I-digested fragment from pBeloaBAC11 (4) into the EcoR I-site of pBR322. The pBRBAC-AB retrieval vector was generated by inserting a 216-bp NdeI/EcoRV- homologous fragment (termed ArmA) and a 330-bp EcoRV/SacI-digested homologous fragment (termed ArmB) into the NdeI/SacI sites of pBRBAC. ArmA and ArmB were PCR amplified from Tyrp-1 BAC1 with primers F3: 5’-TTATATGGCATAATCTCCACGTGTC-3’ (italics indicating the NdeI site), R3: 5’-TTATATCGAAGAGATTTTCTCAGACGC-3’ (italics indicating the EcoRV site), F5: 5’-TGATATCTCATTTCTACGGCAG-3’ (italics indicating the EcoRV site), and R5: 5’-GAGCTCAAGCAAAATAAAAACC-3’ (italics indicating the SacI site). The ArmA-Amp-ori-Sp6-ArmB targeting cassette used for retrieving the 22.5kb of Tyrp-1 gene was amplified
from pBRRBAC-AB retrieval vector with primers R3 & F5 (see above). PCR products were purified using a QIA quick PCR Purification Kit (QIAGEN) and digested with DpnI to remove DNA template. The linearized ArmA-Tyrp-1-ArmB-Sp6 targeting cassette used for targeting into the 5' end of Tyrp-1 gene in Tyrp-1 BAC2 was generated by digestion with NotI.

Preparation of the competent cells DY380 and generation of recombinants

For BAC modification, DY380 were transformed with Tyrp-1 BAC1 and Tyrp-1 BAC2 separately. A single colony was cultured in LB (+Cm) at 32°C for 16 hours, then diluted 50-fold in LB medium (+Cm) and grown to an OD600=0.5-0.7. 10ml cultures were exposed to 42°C for 15 minutes to induce recombination activity, then chilled on ice for 20min. Cells were then centrifuged for 8 minutes, 5,500g, at 4°C and washed with 1 ml ice-cold sterile 10% glycerol for three times. Cells were resuspended in 80 µl ice-cold sterile 10% glycerol containing 100 ng linear DNA and electroporated. One ml of LB-media was added after electroporation. Cells were incubated at 32°C for 1.5 hours with shaking then spread on appropriate selective agar media.

PCR and Sequence analysis

BAC DNAs were purified with QIAGEN® Plasmid Purification Maxi kits. Tyrp-1 BAC was sequenced using an ABI 310 Sequencer with primers (F1, R1, F2, R2, F4, F5, R5 and Sp6) to confirm the position and orientation of the 22.5kb fragment inserted into Tyrp-1 BAC2. Primers were F1: 5’-TCTAGACTTTTCTGTTTAATGTT-3’, R1: 5’-TAATGAGGCTTCAATGACTAGATTC-3’, F2: 5’-GCCTCAGATAACAATTCCCTCTAC-3’, R2: 5’-GCGCAATGTCACACTTGTATTTTCTG-3’, F4: 5’-CAGGCAACCTCGGGAGGTGAG-3’, Sp6: 5’-ATTTAGGTGACACTATAG-3’. Primers used for checking the second round recombination events were F6: 5’-ATACAAACTGATGCACCATTCTG-3’ and R6: 5’-CTGGACTGTTGTAGCAGGTG-3’;
F7: 5′-ACACTGCAGACGATAAAATC-3′ and BAC-Sp6-R: 5′-ACGTTTCAGCTGGATATTACGGC-3′.

Results

The general strategy for generating the full length Tyrp-1 gene is shown in Figure 1A-D. The starting materials were two different BACs, both more than 100 kb in length. Tyrp-1 BAC1 contained the exons 1-8 of the Tyrp-1 gene, whilst Tyrp-1 BAC2 contained the upstream regulatory regions together with exons 1 and 2 of the Tyrp-1 gene. The BACs were sequenced using T7 and Sp6 universal primers to confirm the orientation and breakpoint of the Tyrp-1 gene. The method for generating the unified BAC containing the full length Tyrp-1 gene is best described by splitting into two steps: retrieval and recombination. Retrieval (1st round) consists of tagging the Tyrp-1 BAC1 with a selectable marker (frt-Kan<sup>8</sup>-frt) and cloning of the Kan<sup>8</sup> tagged 22,463-bp DNA sequence into a retrieval vector, pBRBAC-AB. Recombination (1st round) consists of the site-specific insertion of this 22,463-bp DNA fragment (3,749-bp frt-Kan<sup>8</sup>-frt cassette + 18,714-bp Tyrp-1 genomic DNA containing a 2,950-bp overlap with Tyrp-1 BAC2) into Tyrp-1 BAC2 followed by the removal of the Kan<sup>8</sup> gene to generate the unified Tyrp-1 BAC. The retrieval-recombination process was then repeated to insert a 19,891-bp DNA fragment (1,896-bp loxP-Kan<sup>8</sup>-loxP cassette + 17,995-bp genomic DNA containing 3,320-bp overlap with the unified Tyrp-1 BAC) further downstream from the previous one. This fragment was retrieved and site-specifically inserted into the unified Tyrp-1 BAC to create the final product, the extended unified Tyrp-1 BAC that has 31,160-bp more Tyrp-1 genomic DNA than the original Tyrp-1 BAC2.

Retrieval

DNA engineering often requires the introduction of a selectable
marker into a targeted gene in order to select the targeted candidate conveniently either in *E. coli* or in mammalian cells (13). Our initial task was to introduce a selectable marker into the targeted gene to facilitate later candidate identification. This would facilitate selection both during retrieval and later recombination into Tyrp-1 BAC2. As the BACs originally encoded Chloramphenicol resistance, a frt-\(Kan^\beta\)-frt cassette was introduced between the eighth exon and polyadenylation site. Red-mediated homologous recombination was facilitated by two regions (70-bp and 500-bp) of homology flanking the frt-\(Kan^\beta\)-frt cassette (Fig. 1B). Approximately 500 Kan\(^\beta\) colonies were obtained from 42°C treated cells, compared to 10 colonies from uninduced cells (Table 1).
Table 1. Efficiency of Homologous Recombination

<table>
<thead>
<tr>
<th>Step</th>
<th>a Number of Colonies obtained</th>
<th>Number of colonies examined</th>
<th>Number of correct colonies</th>
<th>bEfficiency (%)</th>
<th>Length of Homology arms</th>
</tr>
</thead>
</table>
|                      | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-induced | Induced | Non-separated

a. Induced DY380 competent cells carrying the modified BAC1 and BAC2 were electroporated with different linear DNA. The total number of colonies obtained is shown.
b. Efficiency is defined as the number of correct recombinants as a percentage of the number of examined colonies.

Homologous recombination was then used to retrieve the 22.5 kb sequence of interest from Tyrp-1 BAC1 containing the newly inserted frt-Kan$^R$-frt cassette, and then insert this fragment into a retrieval vector. pBR322 was used as the backbone of the retrieval vector due to its low copy number which had low toxicity to the bacterial strain when carrying a very large fragment (10). The retrieval vector contained an ampicillin resistance gene, an origin of replication, a Sp6 fragment to facilitate sequencing, and two homologous end sequences, one from the breakpoint of Tyrp-1 BAC1.
and one from the region 4kb downstream from the stop codon (encoding 216-bp and 330-bp of homology, respectively). A linearized vector was generated by PCR amplification using the R3 and F5 primers. This linearized retrieval vector was transformed into DY380 competent cells carrying Tyrp-1 BAC1, the transformants were then selected on LB-media plates containing both kanamycin and ampicillin. Homologous recombination generated a circular plasmid consisting of the 22.5kb Tyrp-1 DNA cloned into pBRBAC-AB (Fig. 1B). In this step, some 3,600 Kan\textsuperscript{R} colonies were obtained from red-induced cells compared to 38 colonies from uninduced cells (Table 1). 26 out of 28 clones examined were correct recombinants (93%). The data indicated that by using homology arms of more than 200-bp in length, a homologous recombination efficiency over 90% could be achieved. This compares to a previously reported 60% efficiency when homology arms of 50-bp in length were used to retrieve a 25kb fragment from a BAC (10), (Table 1, supra). Representative results are shown in Figure 2A, left panel. Digestion of six retrieved colonies with Sac I and EcoRV showed that only one had an abnormal digestion pattern (Expected digestion pattern for Sac I: 15,189-bp, 5,787-bp and 4,417-bp; for EcoRV :16,975-bp, 6,248-bp and 2,173-bp).

Recombination

After the cloning of the 22.5 kb Tyrp-1 fragment, the pBRBAC-AB vector containing the retrieved fragment was linearized by NotI digestion (right panel, Figure 2A) and transformed into DY380 cells containing Tyrp-1 BAC2. Homologous recombination occurred between the retrieved Tyrp-1 DNA and Tyrp-1 BAC2 through the 216-bp ArmA and the 303-bp Sp6 fragment to give rise to the Tyrp-1 BAC3 (Fig. 1C). Kanamycin and chloramphenicol double resistant colonies were selected. Over 1,500 Km\textsuperscript{R}+Cm\textsuperscript{R} colonies were obtained from the induced cells; no colonies were obtained from uninduced cells (Table 1, supra). PCR amplification was used to determine whether the 22.5kb Tyrp-1 DNA fragment was inserted precisely into Tyrp-1 BAC2.
Several pairs of primers at different positions were used. Results from the PCR amplification showed that the recombination occurred as expected in 10 of 11 clones examined. A full-length Tyrp-1 gene was obtained in Tyrp-1 BAC3 (Fig. 2B). Moreover, one of the recombinant BAC was further analyzed by DNA fingerprinting (Fig. 2C) and sequencing (data not shown). The data showed that the retrieved 22.5kb DNA fragment had been precisely inserted into the Tyrp-1 BAC2 by homologous recombination. These data indicated that this targeting reaction was very efficient due to the longer homologous recombination arms between the targeting fragment and Tyrp-1 BAC2.

Although the selectable marker provides an easy method to select the targeted colonies, it might have interfered with Tyrp-1 gene expression (13) and with the next round of recombination. Selectable markers were therefore removed after targeting to eliminate any undesirable effects. Tyrp-1 BAC3 DNA was introduced into E. coli strain 294-Flp (12), which can express Flp recombinase to excise the kanamycin gene between the two flr sites, leaving only one flr site behind. This resulted in the unified Tyrp-1 BAC containing both the upstream regulatory elements and the eight coding exons.

In order to further validate the approach, a second 19,891-bp DNA fragment was inserted into the unified BAC to precisely add sequence 3' to the coding region. A loxP-Kan^R-loxP cassette was inserted into the original Tyrp-1 BAC1 DNA at a position approximately 17-kb downstream of the poly(A) site to facilitate the retrieval. A second-round retrieval and recombination was carried out to generate the final product, the extended unified Tyrp-1 BAC (Figure 1D). The recombination products were verified by PCR (Figure 2D). Efficiency comparable to the first round of retrieval-recombination was obtained (data not shown).
Discussion

A unified Tyrp-1 BAC containing an intact gene has been generated by a two-step recombinogenic method. These results show that it is feasible to retrieve large DNA fragments from one BAC and precisely insert them into other BACs using Red-mediated homologous recombination. The design of the retrieval vector was the most important factor for subsequent homologous recombination. Insertion of the Sp6 fragment into pBR322 was vital as it incorporates the rare cutter NolI restriction site enabling later linearization of the retrieval plasmid, and provides a homologous arm for directional insertion of the retrieved DNA fragment into BACs. This data also indicates that longer homologous arms can generate more recombinant colonies as well as higher recombination efficiencies.

After removing the selectable marker in the Tyrp-1 BAC3 to generate the unified Tyrp-1 BAC, another round of retrieval-recombination can be carried out. The frt site left in Tyrp-1 BAC can be removed after the second round of recombination facilitated by a long homologous region upstream of the frt site (Figure 1D). Through two rounds of retrieval-recombination, a total of 31,160-bp of genomic DNA from Tyrp-1 BAC1 was inserted into Tyrp-1 BAC2 in a site-specific manner. Since the loxP-Kan\(^R\)-LoxP sequence can be removed similarly to the frt-Kan\(^R\)-frt sequence, the approach described herein allows multiple rounds of retrieval-recombination, effectively enabling the construction of very large BACs limited only by the nature of the BAC backbone vector.

This method is not limited to BAC manipulation, it could be used to engineer any large DNA fragments or to insert large DNA fragments into the E. coli chromosome. With suitable vectors, this method may be used to construct and modify much larger DNA molecules such as Human Artificial Chromosomes (HAC). In this study, the templates
for genomic DNA retrieval and recombination were BACs obtained through a library screen. However, it would be possible to avoid the library screen steps and generate these large DNA molecules by long range PCR or by direct recombinogenic retrieval from a complex genomic DNA mixture (14). Due to its simplicity, speed and precision, the method represents a powerful approach for BAC manipulation to aid in future studies of gene function in the post-genomic era.

The following references have been referred to throughout the specification. The entire content of these references is hereby incorporated by reference herein as background and illustrative of the state of the art of the invention.
REFERENCES


10. Lee, E.C., Yu, D., Martinez de Velasco, J., Tessarollo, L.,


WE CLAIM:

1. A method for combining overlapping DNA molecules comprising the steps of:
   (a) providing first and second DNA fragments, the first having a region homologous to a region in the second;
   (b) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex;
   (c) linearizing the DNA-vector complex; and
   (d) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule.

2. A method in accordance with claim 1, wherein the nucleic acid fragments are genomic DNAs.

3. A method in accordance with claim 1, wherein the nucleic acid fragments are cDNAs.

4. A method in accordance with claim 1, wherein the nucleic acid fragments comprise at least 20 kb.

5. A method in accordance with claim 1, wherein the nucleic acid fragments comprise bacterial artificial chromosomes (BACs), mouse artificial chromosomes (MAC) or human artificial chromosomes (HACs).

6. A method in accordance with claim 1, wherein the retrieval vector comprises an Sp6 fragment.

7. A method in accordance with claim 1, wherein the homologous recombination is Red-mediated homologous recombination.
8. The method in accordance with claim 1 further comprising the step of inserting the combined DNA molecule into a third DNA fragment using homologous recombination.

9. A method for combining overlapping DNA molecules comprising the steps of:
   (a) providing first and second DNA fragments, the first having a region homologous to a region in the second;
   (b) tagging the first DNA fragment with a selectable marker;
   (c) cloning the first DNA sequence into a retrieval vector to form a DNA-vector complex;
   (d) linearizing the DNA-vector complex;
   (e) inserting the first DNA fragment from the DNA-vector complex into the second DNA fragment using homologous recombination to form a combined DNA molecule; and
   (f) removing the selectable marker, thereby generating a combined DNA molecule.

10. A method in accordance with claim 9, wherein the nucleic acid fragments are genomic DNAs.

11. A method in accordance with claim 9, wherein the DNA fragments are cDNAs.

12. A method in accordance with claim 9, wherein the DNA fragments comprise at least 20 kb.

13. A method in accordance with claim 9, wherein the DNA fragments comprise bacterial artificial chromosomes (BACs), mouse artificial chromosomes (MAC) or human artificial chromosomes (HACs).
14. A method in accordance with claim 9, wherein the retrieval vector comprises an Sp6 fragment.

15. A method in accordance with claim 9, wherein the homologous recombination is Red-mediated homologous recombination.

16. A method in accordance with claim 9 further comprising the step of inserting the combined DNA molecule into a third DNA fragment using homologous recombination.

17. A vector for retrieving and inserting a selected DNA molecule into a target DNA molecule, comprising:
   (a) a first DNA fragment homologous with a first region of the selected DNA molecule;
   (b) a second DNA fragment homologous with a second region of the selected DNA molecule; and
   (c) a third DNA fragment containing a rare restriction site.

18. A vector in accordance with claim 17, wherein the third DNA fragment is an Sp6 fragment.

19. A vector in accordance with claim 17, wherein the rare restriction site is NotI.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl \(^7\) C12N 15/09

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl \(^7\) C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Epoque(WPI, EPDOC, PAJ), Medline, Biological Abstracts

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO9808964 A1 (OKAZAKI, Tsuneko, et al). 5 March 1998 (05.03.1998) Referring to example 2,3 and figure 7,9,12-15</td>
<td>1-4,6-12,14-17</td>
</tr>
<tr>
<td>X</td>
<td>WO00026396 A1 (THE MURDOCH INSTITUTE). 11 May 2000 (11.05.2000) Referring to Figure 1</td>
<td>17-19</td>
</tr>
<tr>
<td>X</td>
<td>Campbell, C., et al. Generation of a nested series of interstitial deletions in yeast artificial chromosomes carrying human DNA. Proc. Natl. Acad. Sci. USA, July 1991, 88: 5744-5748. (referring to Figure 2)</td>
<td>1-4,6-12,14-17</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may have doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16. Sept. 2004

Date of mailing of the international search report

30 • SEP 2004 (30 • 09 • 2004)

Name and mailing address of the ISA/

6 Xizheng Road Haidian District
Beijing P.R. China 100088

Facsimile No. (86-10)62019451

Form PCT/ISA/210 (second sheet) (January 2004)

Authorized officer

Wu Yongqing

Telephone No. (86-10)62085070
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO9808964 A1</td>
<td>05.03.1998</td>
<td>AU6755096 A</td>
<td>19.03.1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP0928339 A</td>
<td>14.07.1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US6297029 B</td>
<td>02.10.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU741864 B</td>
<td>13.12.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US2002076811 A</td>
<td>20.06.2002</td>
</tr>
<tr>
<td>WO0026396 A1</td>
<td>11.05.2000</td>
<td>AU6321099 A</td>
<td>22.05.2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP1127152 A</td>
<td>08.29.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN1331748 A</td>
<td>16.01.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP2002528129 A</td>
<td>03.09.2002</td>
</tr>
</tbody>
</table>